Treats major depressive disorder. ANDA 78627, held by Sun Pharmaceutical Industries. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 78627 (Venlafaxine Hydrochloride), held by Sun Pharmaceutical Industries, was first approved by FDA on Jun 13, 2008, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Venlafaxine tablets, USP is indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6 week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4 week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 13, 2008 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 25MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 37.5MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 50MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 75MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 100MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Aug 21, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 21, 2021 | Supplement 14Labeling · Standard review | Approved | None posted |
| Sep 2, 2021 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 4, 2017 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 17, 2014 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 8, 2009 | Supplement 2Labeling | Approved | None posted |
| Jun 13, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters